On 1 April 2020, the FAMHP took steps regarding a range of medicinal products in order to avoid any shortage. These measures have now been extended by one month.
Stocks of medicinal products used to treat COVID-19 patients have been closely monitored by the FAMHP since the onset of the COVID-19 crisis.
As of 1 April 2020, the FAMHP has drawn up a list of medicinal products and raw materials used in the treatment of COVID-19 for which emergency measures have been taken. These measures have then been refined and extended. Since mid-June 2020, these are mainly measures relating to quotas for wholesalers. The latest adaptation of the list of products also includes dexamethasone. The new decision extends the measure until 28 July 2020.
Thanks to these measures and their extension, solutions and alternatives for all the medicinal products necessary for the treatment of COVID-19 patients in Belgium currently exist and will exist in the near future.